Overview

Autologous Tumor Tissue Antigen-sensitized DC-CIK Cells Combined With Chemotherapy for Esophageal Cancer

Status:
Unknown status
Trial end date:
2019-05-01
Target enrollment:
Participant gender:
Summary
This study evaluates the safety and efficacy of D-CIK immune cells combined with chemotherapy after resection of esophageal cancer
Phase:
Phase 2
Details
Lead Sponsor:
Shenzhen Hornetcorn Bio-technology Company, LTD
Collaborators:
Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Affiliated Tumor Hospital of Guangzhou Medical University
Treatments:
Albumin-Bound Paclitaxel
Cisplatin
Paclitaxel